Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HW252001 in healthy subjects
NCT07493031Phase 1Not yet recruiting
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing HW252001 with Placebo (2 arms). Primary endpoint: Number and severity of treatment emergent adverse events at 11 days. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
HW252001
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT07493031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493031.